Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors (MMF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03971591
Recruitment Status : Recruiting
First Posted : June 3, 2019
Last Update Posted : August 13, 2019
Sponsor:
Collaborators:
Loyola University Chicago
Marquette University
University of Illinois at Chicago
Information provided by (Responsible Party):
Melinda Stolley, Medical College of Wisconsin

Brief Summary:
This study will examine the efficacy of Men Moving Forward (MMF), a four-month community-based lifestyle intervention designed for AA PC survivors. MMF is rooted in the evidence-based Moving Forward lifestyle intervention developed with and for AA breast cancer survivors. This intervention was adapted in collaboration with AA PC survivors. It will offer twice weekly sessions aimed at supporting adherence to the ACS nutrition and physical activity guidelines to promote improved body composition (i.e., decreased adiposity, increased lean mass).

Condition or disease Intervention/treatment Phase
Prostate Cancer Behavioral: Guided Lifestyle Program Intervention Not Applicable

Detailed Description:

Aim 1. To examine the efficacy of the Men Moving Forward guided intervention, as compared to a self-guided control intervention, in producing significant post-intervention changes in body composition in 200 AA PC survivors.

Hypothesis: Men randomized to the guided arm will exhibit significant post-intervention decreases in adiposity and increases in lean body mass compared to men randomized to the control arm.

Aim 2. To investigate the effects of participation in the Men Moving Forward guided intervention on health behaviors and quality of life outcomes.

Hypothesis: Men in the guided program will exhibit increased intake of fruits and vegetables and decreased intake of red meat/processed meat, greater levels of physical activity (minutes per week and #times/wk resistance training) and improved quality of life (targeting physical function, social isolation, sexual functioning) compared to men in the control arm.

Aim 3. To explore the effects of the intervention program on blood pressure, blood lipids, fasting glucose, and biomarkers associated with comorbidities and carcinogenesis (i.e adiponectin, leptin, C-peptide, IGF-1, IGFBP-3, C-Reactive Protein, estradiol, testosterone and sex hormone binding globulin)

Hypothesis: Men in the guided arm will exhibit greater improvements in biomarkers associated with chronic disease and carcionogenesis compared to men in the self-guided control arm.

Men Moving Forward supports PC survivors in adopting physical activity and eating patterns that will improve their body composition, bolster QOL and reduce risk for comorbidities and, potentially, PC recurrence.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomized to either a guided or self-guided lifestyle intervention
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
Actual Study Start Date : June 1, 2019
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Guided Lifestyle program
The Intervention will be conducted in cohorts of 15-20. We anticipate there will be 5-6 cohorts over the course of the study. Men assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies, the second hour will be supervised exercise with strength training. The second weekly session will be a one-hour supervised exercise session with strength training. Men will also receive 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
Behavioral: Guided Lifestyle Program Intervention
The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.

Active Comparator: Self-Guided Lifestyle program
In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging. The study team will call these participants once a month to check in.
Behavioral: Guided Lifestyle Program Intervention
The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.




Primary Outcome Measures :
  1. Change in body composition [ Time Frame: Change from Baseline to 4 month ]
    Ratio of percent lean mass to percent adiposity as measured by DEXA. More lean mass and less adiposity is favorable.

  2. Change in body composition [ Time Frame: Change from Baseline to 12 month ]
    Ratio of percent lean mass to percent adiposity as measured by DEXA. More lean mass and less adiposity is favorable.

  3. Increase in intake of fruits and vegetables [ Time Frame: Change from Baseline to 4 month ]
    VioScreen's dietary analysis of self reported food consumption

  4. Increase in intake of fruits and vegetables [ Time Frame: Change from Baseline to 12 month ]
    VioScreen's dietary analysis of self reported food consumption

  5. Decrease of intake of red meat/processed meat [ Time Frame: Change from Baseline to 4 month ]
    VioScreen's dietary analysis of self reported food consumption

  6. Decrease of intake of red meat/processed meat [ Time Frame: Change from Baseline to 12 month ]
    VioScreen's dietary analysis of self reported food consumption

  7. Increase in levels of physical activity- minutes per week [ Time Frame: Change from Baseline to 4 month ]
    Change of ActiGraph monitored activity

  8. Increase in levels of physical activity- minutes per week [ Time Frame: Change from Baseline to 12 month ]
    Change of ActiGraph monitored activity

  9. Increase in levels of physical activity- #times per week [ Time Frame: Change from Baseline to 4 month ]
    Change of ActiGraph monitored activity

  10. Increase in levels of physical activity- #times per week [ Time Frame: Change from Baseline to 12 month ]
    Change of ActiGraph monitored activity

  11. Increase in resistance training- Lower extremity strength [ Time Frame: Change from Baseline to 4 month ]
    Isokinetic dynamometer (HUMAC Norm, Stoughton, MA).

  12. Increase in resistance training- Lower extremity strength [ Time Frame: Change from Baseline to 12 month ]
    Isokinetic dynamometer (HUMAC Norm, Stoughton, MA).

  13. Increase in resistance training- Handgrip strength [ Time Frame: Change from Baseline to 4 month ]
    Takei 5401 Hand Grip Digital Dynamometer

  14. Increase in resistance training- Handgrip strength [ Time Frame: Change from Baseline to 12 month ]
    Takei 5401 Hand Grip Digital Dynamometer

  15. Increase in resistance training- Strength and endurance [ Time Frame: Change from Baseline to 4 month ]
    30-Second Chair Stand (Sit to Stand)

  16. Increase in resistance training- Strength and endurance [ Time Frame: Change from Baseline to 12 month ]
    30-Second Chair Stand (Sit to Stand)

  17. Change in Quality of Life- PROMIS [ Time Frame: Change from Baseline to 4 month ]
    PROMIS T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. PROMIS measures physical function, depression, anxiety, fatigue, sleep disturbance, social roles, pain interference, social isolation, cognitive function, support, self-efficacy and sexual function.

  18. Change in Quality of Life-PROMIS [ Time Frame: Change from Baseline to 4 month ]
    PROMIS T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. PROMIS measures physical function, depression, anxiety, fatigue, sleep disturbance, social roles, pain interference, social isolation, cognitive function, support, self-efficacy and sexual function.

  19. Change in Urban life stress inventory- Crisys [ Time Frame: Change from Baseline to 4 month ]
    Measure change of mean in positive/negative/neutral and resolved/ongoing

  20. Change in Urban life stress inventory-Crisys [ Time Frame: Change from Baseline to 12 month ]
    Measure change of mean in positive/negative/neutral and resolved/ongoing

  21. Changes in Blood Pressure [ Time Frame: Change from Baseline to 4 month ]
    Participants blood pressure will be measured using a digital, automated unit

  22. Change in Blood Pressure [ Time Frame: Change from Baseline to 12 month ]
    Participants blood pressure will be measured using a digital, automated unit

  23. Change in Biomarkers- Hemoglobin [ Time Frame: Change from Baseline to 4 month ]
    Hemoglobin blood tests measured by Wisconsin Diagnostic Laboratory

  24. Change in Biomarkers-Hemoglobin [ Time Frame: Change from Baseline to 12 month ]
    Hemoglobin blood tests measured by Wisconsin Diagnostic Laboratory

  25. Change in Biomarkers- A1C [ Time Frame: Change from Baseline to 4 month ]
    A1C blood tests measured by Wisconsin Diagnostic Laboratory

  26. Change in Biomarkers- A1C [ Time Frame: Change from Baseline to 12 month ]
    A1C blood tests measured by Wisconsin Diagnostic Laboratory

  27. Change in Biomarkers- Hormones-Testosterone [ Time Frame: Change from Baseline to 4 month ]
    Testosterone blood test measured by Wisconsin Diagnostic Laboratory

  28. Change in Biomarkers- Hormones-Testosterone [ Time Frame: Change from Baseline to 12 month ]
    Testosterone blood test measured by Wisconsin Diagnostic Laboratory

  29. Change in Biomarkers- Hormones- Estradiol [ Time Frame: Change from Baseline to 4 month ]
    Estradiol blood test measured by Wisconsin Diagnostic Laboratory

  30. Change in Biomarkers- Hormones- Estradiol [ Time Frame: Change from Baseline to 12 month ]
    Estradiol blood test measured by Wisconsin Diagnostic Laboratory

  31. Change in Biomarkers- Hormones- SHBG [ Time Frame: Change from Baseline to 4 month ]
    SHBG blood test measured by Wisconsin Diagnostic Laboratory

  32. Change in Biomarkers- Hormones- SHBG [ Time Frame: Change from Baseline to 12 month ]
    SHBG blood test measured by Wisconsin Diagnostic Laboratory

  33. Change in Biomarkers-Adipokines- Leptin [ Time Frame: Change from Baseline to 4 month ]
    Leptin blood test measured by Wisconsin Diagnostic Laboratory

  34. Change in Biomarkers-Adipokines- Leptin [ Time Frame: Change from Baseline to 12 month ]
    Leptin,blood test measured by Wisconsin Diagnostic Laboratory

  35. Change in Biomarkers-Adipokines-Adiponectin [ Time Frame: Change from Baseline to 4 month ]
    Adiponectin blood test measured by Wisconsin Diagnostic Laboratory

  36. Change in Biomarkers-Adipokines-Adiponectin [ Time Frame: Change from Baseline to 12 month ]
    Adiponectin blood test measured by Wisconsin Diagnostic Laboratory

  37. Change in Biomarkers-Inflammation- IL-6 [ Time Frame: Change from Baseline to 4 month ]
    IL-6 blood test measured by Wisconsin Diagnostic Laboratory

  38. Change in Biomarkers-Inflammation- IL-6 [ Time Frame: Change from Baseline to 12 month ]
    IL-6 blood test measured by Wisconsin Diagnostic Laboratory Wisconsin

  39. Change in Biomarkers-Inflammation-TNFα [ Time Frame: Change from Baseline to 4 month ]
    TNFα blood test measured by Wisconsin Diagnostic Laboratory

  40. Change in Biomarkers-Inflammation-TNFα [ Time Frame: Change from Baseline to 12 month ]
    TNFα blood test measured by Wisconsin Diagnostic Laboratory

  41. Change in Biomarkers-Insulin Resistance-C-Peptide [ Time Frame: Change from Baseline to 4 month ]
    C-Peptide blood test measured by Wisconsin Diagnostic Laboratory

  42. Change in Biomarkers-Insulin Resistance- C-Peptide [ Time Frame: Change from Baseline to 12 month ]
    C-Peptide blood test measured by Wisconsin Diagnostic Laboratory

  43. Change in Biomarkers-Insulin Resistance-IGF-1 [ Time Frame: Change from Baseline to 4 month ]
    IGF-1 blood test measured by Wisconsin Diagnostic Laboratory

  44. Change in Biomarkers Insulin Resistance-IGF-1 [ Time Frame: Change from Baseline to 12 month ]
    IGF-1 blood test measured by Wisconsin Diagnostic Laboratory



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Male Prostate Cancer study participants
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years and older
  • Self-identify as Black or African American
  • Diagnosed with non-metastatic Prostate Cancer (cancer that has NOT spread elsewhere in the body)
  • Completed all treatments (including Androgen Deprivation Therapy) at least six months prior to enrollment
  • BMI > 25 kg/m2
  • Able to participate in moderate physical activity as assessed by healthcare provider
  • Exercise less than the ACS recommended guideline of 150 min/week or 30 min/day.
  • Fruit and vegetable consumption is less than 5 servings each day.
  • Lift Weights or engage in strength training less than twice a week.
  • Can walk continuously for 5 minutes without stopping because of pain or shortness of breath.
  • Have access to a mobile phone
  • Approval from Primary Care Provider/Medical Oncologist
  • Available to attend intervention

Exclusion Criteria:

  • • Does not meet the Inclusion Criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03971591


Contacts
Layout table for location contacts
Contact: Jo Bergholte, MLIS 414-805-6990 jbergholte@mcw.edu
Contact: Kathleen Jensik, MSW 414-955-2114 kjensik@mcw.edu

Locations
Layout table for location information
United States, Wisconsin
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Tina Johnson    414-955-4095    jojohnso@mcw.edu   
Contact: Kathleen Jensik, MSW    414-955-2114    kjensik@mcw.edu   
Principal Investigator: Melinda Stolley, PhD         
Sponsors and Collaborators
Medical College of Wisconsin
Loyola University Chicago
Marquette University
University of Illinois at Chicago

Layout table for additonal information
Responsible Party: Melinda Stolley, Associate Director for Cancer Prevention and Control, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT03971591     History of Changes
Other Study ID Numbers: PRO00031416
First Posted: June 3, 2019    Key Record Dates
Last Update Posted: August 13, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases